Lapteva N - Search Results

1

CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.

Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. Lapteva N, et al. Cancer Gene Ther. 2005 Jan;12(1):84-9. doi: 10.1038/sj.cgt.7700770. Cancer Gene Ther. 2005. PMID: 15472715

2

SOCS1 downregulation in dendritic cells promotes memory T-cell responses.

Aldrich M, Sanders D, Lapteva N, Huang XF, Chen SY. Aldrich M, et al. Among authors: lapteva n. Vaccine. 2008 Feb 20;26(8):1128-35. doi: 10.1016/j.vaccine.2007.11.020. Epub 2007 Dec 7. Vaccine. 2008. PMID: 18222020 Free PMC article.

3

Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. Lapteva N, et al. J Immunother. 2009 Feb-Mar;32(2):145-56. doi: 10.1097/CJI.0b013e318193d31e. J Immunother. 2009. PMID: 19238013 Free PMC article.

4

Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.

Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF. Lapteva N, et al. Mol Ther. 2009 Sep;17(9):1626-36. doi: 10.1038/mt.2009.111. Epub 2009 Jun 16. Mol Ther. 2009. PMID: 19532135 Free PMC article.

5

Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation.

Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Lapteva N, et al. Cancer Res. 2007 Nov 1;67(21):10528-37. doi: 10.1158/0008-5472.CAN-07-0833. Cancer Res. 2007. PMID: 17974997

6

Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples.

Lyon D, Lapteva N, Gee AP. Lyon D, et al. Among authors: lapteva n. Mol Ther. 2018 Jan 3;26(1):6-7. doi: 10.1016/j.ymthe.2017.12.003. Epub 2017 Dec 9. Mol Ther. 2018. PMID: 29301109 Free PMC article. No abstract available.

7

An essential role for Akt1 in dendritic cell function and tumor immunotherapy.

Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. Park D, et al. Among authors: lapteva n. Nat Biotechnol. 2006 Dec;24(12):1581-90. doi: 10.1038/nbt1262. Epub 2006 Dec 3. Nat Biotechnol. 2006. PMID: 17143278

8

Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Miller JS, et al. Among authors: lapteva n. Biol Blood Marrow Transplant. 2014 Aug;20(8):1252-7. doi: 10.1016/j.bbmt.2014.05.004. Epub 2014 May 9. Biol Blood Marrow Transplant. 2014. PMID: 24816582 Free PMC article.

9

Clinical grade purification and expansion of natural killer cells.

Lapteva N, Szmania SM, van Rhee F, Rooney CM. Lapteva N, et al. Crit Rev Oncog. 2014;19(1-2):121-32. doi: 10.1615/critrevoncog.2014010931. Crit Rev Oncog. 2014. PMID: 24941378 Free PMC article. Review.

10

Optimization manufacture of virus- and tumor-specific T cells.

Lapteva N, Vera JF. Lapteva N, et al. Stem Cells Int. 2011;2011:434392. doi: 10.4061/2011/434392. Epub 2011 Sep 11. Stem Cells Int. 2011. PMID: 21915183 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters